Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service

Pill Taken By Millions Of Diabetics Could Halve Alzheimer’s Risk

Actos, also known as Poglitazone in medicine, reduces mental deterioration and lowers rates of the disease that steals memory

Zenger

Diabetes drug could be a 'game changer' in the fight to prevent Alzheimer's

Research undertaken in South Korea shows that taking pioglitazone may help reduce the onset of dementia

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune

Alzheimer’s study in Boston looking at possible treatment to prevent the disease

BOSTON — Boston medical researchers are hoping to get ahead of Alzheimer’s by testing a possible treatment in patients who don’t have symptoms but may be at risk for the progressive disease.

Boston Herald

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

Tribune News Service

Alzheimer's: blood biomarker may help identify the disease ten years before symptoms start

Though Alzheimer’s disease affects more than 55 million people worldwide, there’s still no cure for the condition – and treatment options are limited.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

The Conversation

A new Alzheimer’s drug has been approved. What to know about lecanemab

A new drug that appears to slow early Alzheimer’s disease is coming to the market.

Tribune News Service

Mayo Clinic expert provides perspective on FDA approval of another experimental Alzheimer's drug

The Food and Drug Administration granted accelerated approval of a disease-modifying treatment that could potentially give some patients with Alzheimer's disease something they haven't had before: a medication that may slow the decline of memory and thinking.

Tribune News Service

Finally, a new drug slows Alzheimer’s, but is it worth the price for modest benefit?

Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until…

Chicago Sun-Times

EXPLAINER: New drug slows Alzheimer's but comes with caveats

A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution

The Independent UK

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

Asharq Al-Awsat

The FDA approved the first Alzheimer’s drug that may really work. A Penn physician explains why you probably can’t get it, yet

The FDA on Friday authorized the use of the Alzheimer’s drug lecanemab, the first drug clearly shown to slow the progress of the debilitating brain disease.

The Philadelphia Inquirer

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

FDA approves Alzheimer's drug that appears to modestly slow disease

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

Bangkok Post

US approves new drug to treat Alzheimer's

WASHINGTON - The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in the early stages of Alzheimer's disease.

The Independent UK

New hope for Alzheimer’s sufferers as FDA gives fast-track approval to experimental drug

The study also showed that Leqembi carries a risk of brain swelling and bleeding

The Independent UK

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

The Independent UK

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Investors Business Daily

Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card

Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi.

Daily Mirror

Participant taking part in experimental trial for Alzheimer's drug dies suddenly

A 65-year-old has died after taking part in an experimental clinical trial for Alzheimer’s disease, with a new study saying their passing could have been related to the drug

Dublin Live

New blood test could pave way for early detection of Alzeimher’s

Scientists claim that the blood test will help flag the disease early on and could eventually replace diagnostic methods such as brain scans

The Philadelphia Inquirer

What to know about the new drug trial for Alzheimer's

PHILADELPHIA — A new drug designed to ward off Alzheimer's is being tested at more than 100 sites around the world, including the University of Pennsylvania.

The Conversation

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

1 2 3 4 5

People

Maria Carrillo

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

University of Pennsylvania

National Institutes of Health

65 stories

US Food and Drug Administration

56 stories

New England Journal of Medicine

29 stories

Leqembi

23 stories

Alzheimer Association

18 stories

Aduhelm

12 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.